192 related articles for article (PubMed ID: 37986944)
1. FOXO1 is a master regulator of CAR T memory programming.
Doan A; Mueller KP; Chen A; Rouin GT; Daniel B; Lattin J; Chen Y; Mozarsky B; Markovska M; Arias-Umana J; Hapke R; Jung I; Xu P; Klysz D; Bashti M; Quinn PJ; Sandor K; Zhang W; Hall J; Lareau C; Grupp SA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
Res Sq; 2023 Nov; ():. PubMed ID: 37986944
[TBL] [Abstract][Full Text] [Related]
2. FOXO1 is a master regulator of memory programming in CAR T cells.
Doan AE; Mueller KP; Chen AY; Rouin GT; Chen Y; Daniel B; Lattin J; Markovska M; Mozarsky B; Arias-Umana J; Hapke R; Jung IY; Wang A; Xu P; Klysz D; Zuern G; Bashti M; Quinn PJ; Miao Z; Sandor K; Zhang W; Chen GM; Ryu F; Logun M; Hall J; Tan K; Grupp SA; McClory SE; Lareau CA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
Nature; 2024 May; 629(8010):211-218. PubMed ID: 38600391
[TBL] [Abstract][Full Text] [Related]
3. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
Zheng W; Wei J; Zebley CC; Jones LL; Dhungana Y; Wang YD; Mavuluri J; Long L; Fan Y; Youngblood B; Chi H; Geiger TL
Blood; 2021 Jul; 138(2):122-135. PubMed ID: 33690816
[TBL] [Abstract][Full Text] [Related]
4. Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability.
Tang J; Sheng J; Zhang Q; Ji Y; Wang X; Zhang J; Wu J; Song J; Bai X; Liang T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849200
[TBL] [Abstract][Full Text] [Related]
5. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
Jung IY; Narayan V; McDonald S; Rech AJ; Bartoszek R; Hong G; Davis MM; Xu J; Boesteanu AC; Barber-Rotenberg JS; Plesa G; Lacey SF; Jadlowsky JK; Siegel DL; Hammill DM; Cho-Park PF; Berger SL; Haas NB; Fraietta JA
Sci Transl Med; 2022 Nov; 14(670):eabn7336. PubMed ID: 36350986
[TBL] [Abstract][Full Text] [Related]
6. Deleting SUV39H1 in CAR-T cells epigenetically enhances the antitumor function.
Wang Y; Zhao G; Wang S; Li N
MedComm (2020); 2024 May; 5(5):e552. PubMed ID: 38645666
[TBL] [Abstract][Full Text] [Related]
7. Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming.
Alvanou M; Lysandrou M; Christophi P; Psatha N; Spyridonidis A; Papadopoulou A; Yannaki E
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046597
[TBL] [Abstract][Full Text] [Related]
8. Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death.
Wang Y; Zhang H; Du G; Luo H; Su J; Sun Y; Zhou M; Shi B; Li HQX; Jiang H; Li Z
Mol Ther; 2023 Mar; 31(3):701-714. PubMed ID: 36523165
[TBL] [Abstract][Full Text] [Related]
9. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.
Alizadeh D; Wong RA; Yang X; Wang D; Pecoraro JR; Kuo CF; Aguilar B; Qi Y; Ann DK; Starr R; Urak R; Wang X; Forman SJ; Brown CE
Cancer Immunol Res; 2019 May; 7(5):759-772. PubMed ID: 30890531
[TBL] [Abstract][Full Text] [Related]
10. Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.
Jain N; Zhao Z; Koche RP; Antelope C; Gozlan Y; Montalbano A; Brocks D; Lopez M; Dobrin A; Shi Y; Gunset G; Giavridis T; Sadelain M
Cancer Discov; 2024 Jan; 14(1):142-157. PubMed ID: 37934007
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
[TBL] [Abstract][Full Text] [Related]
12. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
13. Active Maintenance of T Cell Memory in Acute and Chronic Viral Infection Depends on Continuous Expression of FOXO1.
Utzschneider DT; Delpoux A; Wieland D; Huang X; Lai CY; Hofmann M; Thimme R; Hedrick SM
Cell Rep; 2018 Mar; 22(13):3454-3467. PubMed ID: 29590615
[TBL] [Abstract][Full Text] [Related]
14. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.
Prinzing B; Zebley CC; Petersen CT; Fan Y; Anido AA; Yi Z; Nguyen P; Houke H; Bell M; Haydar D; Brown C; Boi SK; Alli S; Crawford JC; Riberdy JM; Park JJ; Zhou S; Velasquez MP; DeRenzo C; Lazzarotto CR; Tsai SQ; Vogel P; Pruett-Miller SM; Langfitt DM; Gottschalk S; Youngblood B; Krenciute G
Sci Transl Med; 2021 Nov; 13(620):eabh0272. PubMed ID: 34788079
[TBL] [Abstract][Full Text] [Related]
15. SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors.
López-Cobo S; Fuentealba JR; Gueguen P; Bonté PE; Tsalkitzi K; Chacón I; Glauzy S; Bohineust A; Biquand A; Silva L; Gouveia Z; Goudot C; Perez F; Saitakis M; Amigorena S
Cancer Discov; 2024 Jan; 14(1):120-141. PubMed ID: 37934001
[TBL] [Abstract][Full Text] [Related]
16. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.
Guedan S; Madar A; Casado-Medrano V; Shaw C; Wing A; Liu F; Young RM; June CH; Posey AD
J Clin Invest; 2020 Jun; 130(6):3087-3097. PubMed ID: 32069268
[TBL] [Abstract][Full Text] [Related]
17. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.
Wei W; Chen ZN; Wang K
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569693
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic reprogramming of CAR T cells for in vivo functional persistence against solid tumors.
Saitakis M
Genes Immun; 2024 Feb; ():. PubMed ID: 38388813
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]